{"aliases":[{"type":"CodeName","name":"SAR650984"},{"type":"USBrandName","name":"Sarclisa"},{"type":"CASRegistryName","name":"1461640-62-9"},{"type":"CodeName","name":"Hu 38SB19"},{"type":"ChemicalStructureName","name":"immunoglobulin G1, anti-(human CD38 antigen) (human-mus musculus monoclonal HU38SB19 heavy chain), disulfide with human-mus musculus monoclonal HU38SB19 light chain, dimer"},{"type":"CodeName","name":"SAR 650984"},{"type":"Synonym","name":"isatuximab"}],"definition":{"html":"A humanized IgG1 monoclonal antibody directed against the cell surface glycoprotein CD-38 with potential antineoplastic activity. Isatuximab-irfc specifically binds to CD38 on CD38-positive tumor cells. This may trigger antitumoral antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and apoptosis eventually leading to cell lysis in CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies, and its expression has been correlated with poor prognosis.","text":"A humanized IgG1 monoclonal antibody directed against the cell surface glycoprotein CD-38 with potential antineoplastic activity. Isatuximab-irfc specifically binds to CD38 on CD38-positive tumor cells. This may trigger antitumoral antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and apoptosis eventually leading to cell lysis in CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies, and its expression has been correlated with poor prognosis."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/isatuximab-irfc","text":"Isatuximab-irfc"},"nciConceptId":"C90578","nciConceptName":"Isatuximab","termId":668181,"name":"isatuximab-irfc","firstLetter":"i","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"isatuximab"}